1. Generics Bulletin
  2. >>Business
  3. >>Deals

Ipca Strikes Biosimilar Technology Transfer Amid Rising Ambitions In The Space

Indian Firm Counts Six MAbs In Its Pipeline, With Two Leading The Pack

 
• By Dean Rudge

Ipca Laboratories underlined its commitment to successfully developing quality and affordable biosimilars meeting global standards as it penned a technology transfer agreement with a fellow Indian firm.

Closeup Of Handshake
• Source: Shutterstock

Ipca Laboratories has entered into a technology transfer agreement with fellow Indian firm Omexa Formulary, granting Omexa non-exclusive rights to research, develop, manufacture and market an oncology biosimilar for the global market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Emcure’s Subsidiary Tillomed Boosts Portfolio With $20m+ Manx Deal

 
• By Adam Zamecnik

The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.

Lupin Boosts UK Presence Through Renascience Acquisition

 
• By Adam Zamecnik

Lupin’s UK subsidiary acquired the British firm for an undisclosed sum of money, adding further assets into the company’s armamentarium.

Viatris Puts Pen To Paper On $335m Opioid Settlement Agreement

 
• By Dean Rudge

Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.

Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition

 
• By Dean Rudge

Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.

More from Business